Effect of p27 deficiency and rapamycin on intimal hyperplasia: In vivo and in vitro studies using a p27 knockout mouse model

Laboratory Investigation

Volumn 81, Issue 6, 2001, Pages 895-903

  Roqué, Mercè ^a   Reis, Ernane D ^a   Cordon Cardo, Carlos ^b   Taubman, Mark B ^a   Fallon, John T ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27; RAPAMYCIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL COUNT; CELL ISOLATION; CELL PROLIFERATION; ENZYME INHIBITION; FEMORAL ARTERY; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034984803     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780298     Document Type: Article

References (53)

1. kip1 synthesis by platelet-derived growth factor in BALB/c3T3 cells
2. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation
3. Cell cycle progression. New therapeutic target for vascular proliferative disease
4. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
5. kip1 function results in increased proliferative capacity of oligodendrocyte progenitors but unaltered timing of differentiation
6. Migration of smooth muscle and endothelial cells: Critical events in restenosis
7. kip1 protein: Prognostic implications in primary breast cancer
8. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
9. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development
10. kip1 inhibitor of neointima formation in the rat carotid artery
11. kip1 for restriction point control of the fibroblast cell cycle
12. kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
13. Mechanism of action of the immunosuppressant rapamycin
14. kip1 -deficient mice
15. Molecular biology of intimal proliferation
16. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
17. Modified elastic tissue-Masson stain
18. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
19. kip1 accumulation during the cell cycle
20. Inhibitors of the Cip/Kip family
21. kip1
22. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
23. Cyclin AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation
24. kip1
25. Roles of cyclin-dependent kinase inhibitors: Lessons from knockout mice
26. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta
27. Regulation of chemotaxis by the platelet-derived growth factor receptor-β
28. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system: Potential targets for therapy?
29. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
30. kip1
31. Cell cycle regulators in vascular disease
32. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
33. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
34. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and Ick cooperate in hematopoietic cell proliferation
35. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides
36. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells
37. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells
38. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
39. kip1
40. kip1 safeguards against inflammatory injury
41. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
42. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice
43. kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
44. Rapamycin inhibits vascular smooth muscle cell migration
45. Neointimal hyperplasia after femoral artery transluminal injury in C57BL/6 and FVB mice
46. Time course of p27 expression after femoral arterial injury in the mouse
47. A mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils
48. Atherosclerosis: An inflammatory disease
49. Inhibitors of mammalian G1 cyclin-dependent kinases
50. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study
51. Expression of cyclin-dependent kinase inhibitors in vascular disease
52. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle